Sign in Subscribe

liquid-biopsy

A collection of 68 issues

Blood protein biomarkers outperform traditional risk models for early CRC detection

Skip to content The CRC Digest Blood protein biomarkers outperform traditional risk models for early CRC detection A protein score developed from 53,073 participants showed superior performance compared to models using age, BMI, smoking, and family history. (Cancer Epidemiol Biomarkers Prev) This content is informational only and does not

Colonoscope-Derived Mucus Detects KRAS Mutations in Precancerous Lesions

Skip to content The CRC Digest Colonoscope-Derived Mucus Detects KRAS Mutations in Precancerous Lesions A prospective pilot study found that mucus collected from the colonoscope sheath during routine colonoscopy serves as a high-fidelity source of cell-free DNA for detecting KRAS-mutated colorectal neoplasia. (Translational Oncology) This content is informational only and

CRC Research Finding

Skip to content The CRC Digest ◇ Tumor Sidedness Affects Liquid Biopsy Interpretation in Metastatic CRC Right-sided and left-sided tumors exhibit distinct molecular profiles, and researchers found that tumor sidedness impacts circulating RAS mutational status and interpretation of liquid biopsy results. (Molecular Diagnosis & Therapy) This content is informational only and

Blood-based DNA methylation test shows promise for early detection

Skip to content The CRC Digest Blood-based DNA methylation test shows promise for early detection A pilot study of 50 participants in Gaza evaluated circulating tumor DNA methylation biomarkers (SEPT9, SPG20, ALX4, MGMT, and RASSF1A) for non-invasive colorectal cancer detection, with multi-gene panels showing improved diagnostic performance. (Clinica Chimica Acta)

CRC Research Finding

Skip to content The CRC Digest ▪ Methylation Biomarkers Show High Sensitivity for Colorectal Cancer Detection The Cologuard assay demonstrates 92% sensitivity for detecting colorectal cancer, both outperforming traditional screening methods through DNA methylation detection. (J Cancer Res Ther) This content is informational only and does not constitute medical advice. Always

Prior anti-EGFR therapy affects HER2-targeted treatment outcomes

Skip to content The CRC Digest ▸ TREATMENT Prior anti-EGFR therapy affects HER2-targeted treatment outcomes — ESMO Open An integrated analysis of the TRIUMPH and MyPathway studies examined how prior treatment with anti-EGFR (epidermal growth factor receptor) therapy affects the effectiveness of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer. The study

Blood test after surgery predicts recurrence in metastatic colorectal cancer

Skip to content The CRC Digest ▪ SCREENING Blood test after surgery predicts recurrence in metastatic colorectal cancer — Cancer Treatment Reviews A systematic review and meta-analysis found that detecting circulating tumor DNA (ctDNA) after surgery for metastatic colorectal cancer strongly predicts which patients will experience recurrence. This molecular residual disease (MRD)

Liquid biopsy predicts which KRAS G12C patients will benefit from targeted therapy

Skip to content The CRC Digest ◆ TRIAL DATA Liquid biopsy predicts which KRAS G12C patients will benefit from targeted therapy — Journal of Clinical Oncology . This blood-based test could help doctors identify which patients are responding to treatment without waiting for scans. What this means If you have a KRAS G12C

Baseline ctDNA profiling informs HER2-targeted therapy outcomes

Skip to content The CRC Digest Baseline ctDNA profiling informs HER2-targeted therapy outcomes TRIUMPH/MyPathway analysis shows baseline circulating tumor DNA and prior anti-EGFR therapy affect pertuzumab plus trastuzumab efficacy in HER2-amplified metastatic colorectal cancer. (ESMO Open) This content is informational only and does not constitute medical advice. Always consult

ctDNA clearance as early biomarker in KRAS G12C colorectal cancer

Skip to content The CRC Digest ctDNA clearance as early biomarker in KRAS G12C colorectal cancer Phase 3 CodeBreaK 300 results link circulating tumor DNA clearance to efficacy and prognosis with sotorasib plus panitumumab. (JCO) This content is informational only and does not constitute medical advice. Always consult your oncologist